• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • Myinsights
  • MYBoard
  • Strategy & Consulting
Select Page

Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in cUTIs Ends Early After Meeting Primary End Point

by MM360 Staff | Jun 2, 2025 | Myeloma News

Source: Pharmacy Times articles A clinical trial shows tebipenem pivoxil hydrobromide (Tebipenem HBr; Spero Therapeutics and GSK) effectively treats complicated urinary tract infections (cUTIs), potentially transforming patient care and reducing hospital costs. Read...

New Jersey Society of Health-System Pharmacy Hosts 2nd Annual Pharmacy Leader and Pharmacy Technician Symposium

by MM360 Staff | Jun 2, 2025 | Myeloma News

Source: Pharmacy Times articles The NJSHP’s 2nd Annual Symposium fosters networking and education for pharmacy professionals, featuring expert insights on compliance and regulation in pharmacy compounding. Read More

Informing Treatment Decisions Using a 14-Gene Assay in Early Non-Small Cell Lung Cancer

by MM360 Staff | Jun 2, 2025 | Myeloma News

Source: Pharmacy Times articles Post Content Read More

ASCO 2025: Oncology Pathway Tools Show Consistent Usage Across Patient Groups

by MM360 Staff | Jun 2, 2025 | Myeloma News

Source: Pharmacy Times articles Laura Momoko Asakura, PharmD, BCOP, BCSPS, discusses the equitable use of oncology treatment pathway tools, highlighting that their utilization remains consistent across patient groups regardless of race, ethnicity, or insurance status....

NCPA Fly-In Amplifies Pharmacists’ Voice on Capitol Hill: Advocacy, Access, and the Fight for Fair Reimbursement

by MM360 Staff | Jun 2, 2025 | Myeloma News

Source: Pharmacy Times articles National Community Pharmacists Association President Jeff Harrell, PharmD, shares insights from this year’s event, highlighting its growing impact, the importance of engaging with policymakers, and the urgent issues facing independent...

FDA Grants Interchangeability Designation to Hadlima, a Biosimilar for Humira

by MM360 Staff | Jun 2, 2025 | Myeloma News

Source: Pharmacy Times articles The FDA designated Hadlima as an interchangeable biosimilar to Humira, enhancing patient access and potential savings for various conditions. Read More
« Older Entries
Next Entries »

Recent Content

  • Utilizing AI in Prostate Cancer Care and Management
  • KITE-363 Shows High Response in B-Cell Lymphoma With Manageable Safety
  • Rilonacept in Recurrent Pericarditis: Mechanism of Action, Patient Management, and Clinical Considerations
  • Zyprexa Added to Standard Antiemetics Reduces Nausea, Vomiting in Radiation
  • Op-Ed: Expand Patient Choice to Lower Medication Costs
  • Sasanlimab-BCG Combo May Delay Recurrence in Bladder Cancer
  • Meta-Analysis Evaluates RSV Viral Load and Symptom Kinetics
  • Personalized Vaccine Elicits Responses in Patients With Kidney Cancer
  • SCIg More Effective Immunoglobulin Option for Immunocompromised Patients With Inborn Errors of Immunity
  • GLP-1 Receptor Agonists Demonstrate Increased Risk of Neovascular Age-Related Macular Degeneration in Diabetes
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT